153 related articles for article (PubMed ID: 30351740)
1. Ipilimumab Induced Hypophysitis: MRI Findings in a Series of 3 Cases.
Wadhwa V
J Ark Med Soc; 2017 May; 113(11):270-272. PubMed ID: 30351740
[TBL] [Abstract][Full Text] [Related]
2. Ipilimumab-induced hypophysitis and ileocolitis: Serial pituitary MRI findings.
Singh D; Hsu CC; Kwan GN; Bhuta S
Neurol India; 2017; 65(1):165-166. PubMed ID: 28084260
[No Abstract] [Full Text] [Related]
3. Checkpoint Inhibitor-Associated Hypophysitis.
Chang LS; Yialamas MA
J Gen Intern Med; 2018 Jan; 33(1):125-127. PubMed ID: 28770379
[No Abstract] [Full Text] [Related]
4. Pituitary enlargement following ipilimumab without long term endocrine dysfunction.
Nogueira E; Menon A; Dede A; Mitra I; Brock C; Larkin J; Morganstein D
Curr Probl Cancer; 2021 Dec; 45(6):100710. PubMed ID: 33622518
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.
Brilli L; Danielli R; Ciuoli C; Calabrò L; Di Giacomo AM; Cerase A; Paffetti P; Sestini F; Porcelli B; Maio M; Pacini F
Endocrine; 2017 Dec; 58(3):535-541. PubMed ID: 28401443
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab-related hypophysitis may precede severe CNS immune attack.
Köessler T; Olivier T; Fertani S; Marinari E; Dutoit V; Dietrich PY
Ann Oncol; 2016 Oct; 27(10):1975-6. PubMed ID: 27358386
[No Abstract] [Full Text] [Related]
7. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis.
Faje A; Reynolds K; Zubiri L; Lawrence D; Cohen JV; Sullivan RJ; Nachtigall L; Tritos N
Eur J Endocrinol; 2019 Sep; 181(3):211-219. PubMed ID: 31176301
[TBL] [Abstract][Full Text] [Related]
8. Pituitary Dysfunction: A Case Series of Immune Checkpoint Inhibitor-Related Hypophysitis in an Emergency Department.
Miller AH; Brock P; Jim Yeung SC
Ann Emerg Med; 2016 Aug; 68(2):249-50. PubMed ID: 27451306
[No Abstract] [Full Text] [Related]
9. Ipilimumab-Induced Secondary Hypophysitis.
Cheema A
Endocr Pract; 2018 Sep; 24(9):854. PubMed ID: 29624100
[No Abstract] [Full Text] [Related]
10. Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors´ treatment: Spectrum of imaging appearances.
Malikova H; Holesta M; Fialova A; Arenbergerova M; Weichet J
Neuro Endocrinol Lett; 2018 Sep; 39(3):196-204. PubMed ID: 30431741
[TBL] [Abstract][Full Text] [Related]
11. Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.
Siddiqui MS; Lai ZM; Spain L; Greener V; Turajlic S; Larkin J; Morganstein DL
J Endocrinol Invest; 2021 Jan; 44(1):195-203. PubMed ID: 32449093
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab-induced hypophysitis, a single academic center experience.
Snyders T; Chakos D; Swami U; Latour E; Chen Y; Fleseriu M; Milhem M; Zakharia Y; Zahr R
Pituitary; 2019 Oct; 22(5):488-496. PubMed ID: 31327112
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune hypophysitis.
Ileana-Dumbrava E; Subbiah V
Lancet Oncol; 2018 Feb; 19(2):e123. PubMed ID: 29413466
[No Abstract] [Full Text] [Related]
14. Review on Recent Topics in Hypophysitis.
Sugihara H
J Nippon Med Sch; 2017; 84(5):201-208. PubMed ID: 29142180
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy-induced autoimmune hypophysitis.
Valecha G; Pant M; Ibrahim U; Atallah JP
J Oncol Pharm Pract; 2019 Jan; 25(1):217-220. PubMed ID: 28825378
[TBL] [Abstract][Full Text] [Related]
16. Primary and Ipilimumab-induced Hypophysitis: A Single-center Case Series.
Atkins P; Ur E
Endocr Res; 2020 Nov; 45(4):246-253. PubMed ID: 32892666
[TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
Nada A; Bhat R; Cousins J
Curr Probl Cancer; 2021 Feb; 45(1):100644. PubMed ID: 32888700
[TBL] [Abstract][Full Text] [Related]
18. [Endocrine side effects of checkpoint inhibitors].
Chen WJY; Krul-Poel YHM; Roth C; Labots M; van den Eertwegh AJM; Dreijerink KMA
Ned Tijdschr Geneeskd; 2019 Oct; 163():. PubMed ID: 31714042
[TBL] [Abstract][Full Text] [Related]
19. Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases.
Pushkarevskaya A; Neuberger U; Dimitrakopoulou-Strauss A; Enk A; Hassel JC
J Immunother; 2017 Sep; 40(7):282-285. PubMed ID: 28604554
[TBL] [Abstract][Full Text] [Related]
20. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy.
Eryılmaz MK; Mutlu H; Salim DK; Musri FY; Tural D; Başsorgun I; Coşkun HŞ
J Oncol Pharm Pract; 2016 Jun; 22(3):533-6. PubMed ID: 25694346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
